EPS for Intercept Pharmaceuticals, Inc. (ICPT) Expected At $-2.58

October 14, 2018 - By olga

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) LogoInvestors sentiment increased to 1.27 in 2018 Q2. Its up 0.12, from 1.15 in 2018Q1. It increased, as 15 investors sold Intercept Pharmaceuticals, Inc. shares while 40 reduced holdings. 25 funds opened positions while 45 raised stakes. 19.65 million shares or 4.20% more from 18.85 million shares in 2018Q1 were reported.
South Dakota Investment Council has 0.05% invested in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) for 28,600 shares. Natixis has invested 0% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Moreover, Raymond James has 0.01% invested in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). National Bank & Trust Of Montreal Can stated it has 0% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Invesco reported 0% stake. 13,742 were accumulated by Macquarie Gp Ltd. Pictet Asset Limited has invested 0.01% of its portfolio in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Rhumbline Advisers owns 21,153 shares. Zurcher Kantonalbank (Zurich Cantonalbank) owns 1,054 shares. Schwab Charles has invested 0.01% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Piedmont Inv Ltd has invested 0% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Winslow Evans And Crocker Incorporated holds 16 shares or 0% of its portfolio. Northwestern Mutual Wealth Management holds 0% or 120 shares. Moreover, Creative Planning has 0% invested in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) for 3,740 shares. Florida-based State Board Of Administration Of Florida Retirement has invested 0% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT).

Analysts expect Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) to report $-2.58 EPS on November, 7.They anticipate $0.31 EPS change or 10.73 % from last quarter’s $-2.89 EPS. After having $-2.58 EPS previously, Intercept Pharmaceuticals, Inc.’s analysts see 0.00 % EPS growth. The stock increased 3.19% or $3.21 during the last trading session, reaching $103.73. About 375,077 shares traded. Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) has risen 19.09% since October 14, 2017 and is uptrending. It has outperformed by 3.47% the S&P500.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Ratings Coverage

Among 7 analysts covering Intercept Pharmaceuticals (NASDAQ:ICPT), 5 have Buy rating, 0 Sell and 2 Hold. Therefore 71% are positive. Intercept Pharmaceuticals had 9 analyst reports since April 17, 2018 according to SRatingsIntel. The stock of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) earned “Outperform” rating by Wedbush on Monday, August 6. The firm has “Outperform” rating by Wedbush given on Tuesday, April 17. The company was downgraded on Tuesday, October 2 by Raymond James. The stock of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) has “Sector Perform” rating given on Wednesday, August 15 by RBC Capital Markets. The firm has “Hold” rating by Laidlaw given on Friday, August 3. Cantor Fitzgerald reinitiated Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) on Monday, October 1 with “Overweight” rating. Goldman Sachs upgraded it to “Buy” rating and $157 target in Monday, August 6 report.

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The company has market cap of $3.07 billion. The Company’s lead product candidate is obeticholic acid , a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). It currently has negative earnings. The firm is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia.

More notable recent Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) news were published by: Seekingalpha.com which released: “CymaBay, GenKyoTex, And Intercept In PBC: The Clinical Differentiation” on October 10, 2018, also Seekingalpha.com with their article: “Premarket analyst action – healthcare” published on October 01, 2018, Fool.com published: “Is Viking Therapeutics the Best NASH Stock to Buy Now?” on September 20, 2018. More interesting news about Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) were released by: Investorplace.com and their article: “5 Biotech Stocks to Play the Sector’s Next Big Trend: NASH” published on September 26, 2018 as well as Seekingalpha.com‘s news article titled: “Intercept And NASH: Itching To The Finish Line” with publication date: September 18, 2018.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>